Structural requirements for B2-agonists with improved degradation stability
- 1 December 1999
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 45 (1-3) , 199-205
- https://doi.org/10.1016/s0162-3109(99)00078-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pharmacological characterization of a nonpeptide bradykinin B2receptor antagonist, FR165649, and agonist, FR190997British Journal of Pharmacology, 1998
- Intravascular and interstitial degradation of bradykinin in isolated perfused rat heartBritish Journal of Pharmacology, 1997
- Degradation of bradykinin by bovine tracheal epithelium and isolated epithelial cellsBritish Journal of Pharmacology, 1997
- Highly Selective Bradykinin Agonists and Antagonists with Replacement of Proline Residues byN-Methyl-d- andl-phenylalanineJournal of Medicinal Chemistry, 1996
- Design of potent, cyclic peptide bradykinin receptor antagonists from conformationally constrained linear peptidesJournal of Medicinal Chemistry, 1993
- Structure‐activity studies on bradykinin and related peptides: agonistsBritish Journal of Pharmacology, 1990
- Metabolism of Bradykinin by Multiple Coexisting Membrane-Bound Peptidases in Lung: Techniques for Investigating the Role of Each Peptidase using Specific InhibitorsAdvances in experimental medicine and biology, 1989
- [Phe8ψ(CH2-NH)Arg9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase IIEuropean Journal of Pharmacology, 1988
- Stabilität verschiedener Bradykininanaloga gegen kininase IICellular and Molecular Life Sciences, 1975
- Analogs of bradykinin containing .beta.-2-thienyl-L-alanineJournal of Medicinal Chemistry, 1971